Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jayne S Gurtler"'
Autor:
Andrew G Shuman, Matti S Aapro, Benjamin Anderson, Katherine Arbour, Pedro C Barata, Aditya Bardia, Eduardo Bruera, Bruce A Chabner, Herbert Chen, Edwin Choy, Pierfranco Conte, Giuseppe Curigliano, Don Dizon, Eileen O’Reilly, Antonio Tito Fojo, Hans Gelderblom, Timothy A Graubert, Jayne S Gurtler, Evan Hall, Fred R Hirsch, Ahmed Idbaih, David H Ilson, Michael Kelley, Carlo La Vecchia, Heinz Ludwig, Beverly Moy, Hyman Muss, Frans Opdam, Rebecca D Pentz, Marshall R Posner, Jeffrey S Ross, Adrian Sacher, Suresh Senan, Enrique Soto-Perez-de-Celis, Kenneth K Tanabe, Jan B Vermorken, Eric Wehrenberg-Klee, Susan E Bates
Publikováno v:
The Oncologist. AlphaMed Press
The oncologist
Shuman, A G, Aapro, M S, Anderson, B, Arbour, K, Barata, P C, Bardia, A, Bruera, E, Chabner, B A, Chen, H, Choy, E, Conte, P, Curigliano, G, Dizon, D, O'Reilly, E, Tito Fojo, A, Gelderblom, H, Graubert, T A, Gurtler, J S, Hall, E, Hirsch, F R, Idbaih, A, Ilson, D H, Kelley, M, La Vecchia, C, Ludwig, H, Moy, B, Muss, H, Opdam, F, Pentz, R D, Posner, M R, Ross, J S, Sacher, A, Senan, S, Perez de Celis, E S, Tanabe, K K, Vermorken, J B, Wehrenberg-Klee, E & Bates, S E 2022, ' Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization ', The Oncologist . https://doi.org/10.1093/oncolo/oyac165
The oncologist
Shuman, A G, Aapro, M S, Anderson, B, Arbour, K, Barata, P C, Bardia, A, Bruera, E, Chabner, B A, Chen, H, Choy, E, Conte, P, Curigliano, G, Dizon, D, O'Reilly, E, Tito Fojo, A, Gelderblom, H, Graubert, T A, Gurtler, J S, Hall, E, Hirsch, F R, Idbaih, A, Ilson, D H, Kelley, M, La Vecchia, C, Ludwig, H, Moy, B, Muss, H, Opdam, F, Pentz, R D, Posner, M R, Ross, J S, Sacher, A, Senan, S, Perez de Celis, E S, Tanabe, K K, Vermorken, J B, Wehrenberg-Klee, E & Bates, S E 2022, ' Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization ', The Oncologist . https://doi.org/10.1093/oncolo/oyac165
In the context of cancer, whether or not to choose pregnancy termination represents a difficult and multifaceted decision. In this editorial, members of The Oncologist editorial team attempt to contextualize the potential implications of the recent S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2ecc854d9ed429acd22943cfd187fb8
https://hdl.handle.net/1887/3563468
https://hdl.handle.net/1887/3563468
Autor:
Borys Hrinczenko, Kevin M. Chin, Anja von Heydebreck, Luc Dirix, Hendrik Tobias Arkenau, Andres Forero-Torres, William Jeffery Edenfield, Petros Nikolinakos, Erika Hamilton, Martin Smakal, Robert Somer, István Takács, Guy Jerusalem, Jayne S. Gurtler, Ralph V. Boccia, Leisha A. Emens, Hans Juergen Grote, Marc E. Lippman
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment
Breast cancer research and treatment
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in pa
Autor:
Nicholas Iannotti, Karen Kelly, Christopher R. Heery, Marcis Bajars, James L. Gulley, Anja von Heydebreck, Jason C. Chandler, Joseph Leach, Isabell Speit, Manish Patel, Jayne S. Gurtler, Jeffrey R. Infante, Ding Wang, Henrik-Tobias Arkenau, Guy Jerusalem, Petros Nikolinakos
Publikováno v:
Cancer Research. 76:CT132-CT132
Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of the immune response against multiple cancers. Avelumab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody currently bei
Autor:
Lucjan Wyrwicz, Jenny Zhang, Young Iee Park, Min-Hee Ryu, Eric Van Cutsem, Alina Muntean, Fortunato Ciardiello, Jean-Marie Cuillerot, Carlos Gomez-Martin, Narikazu Boku, Julien Taieb, Yung-Jue Bang, Rosine Guimbaud, Jayne S. Gurtler, Huiling Xiong
Publikováno v:
Journal of Clinical Oncology. 34:TPS4135-TPS4135
TPS4135Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...
Autor:
Markus Moehler, Julien Taieb, Jenny Zhang, Narikazu Boku, Jean-Marie Cuillerot, Huiling Xiong, Jayne S. Gurtler
Publikováno v:
Journal of Clinical Oncology. 34:TPS4134-TPS4134
TPS4134Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...
Autor:
Kevin M. Chin, Anja von Heydebreck, Ding Wang, Joseph Leach, Isabell Speit, Jayne S. Gurtler, Guy Jerusalem, Hendrik-Tobias Arkenau, Jeffrey R. Infante, Petros Nikolinakos, Jason C. Chandler, James L. Gulley, Manish R. Patel, Karen Kelly, Nicholas Iannotti, Christopher R. Heery
Publikováno v:
Journal of Clinical Oncology. 33:3044-3044
3044 Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of the immune response against multiple cancers. Avelumab* (MSB0010718...
Autor:
Peter Kennedy, Doreen M. Hallman, Brent G. Burger, Nancy E. Kemeny, Howard S. Hochster, Al B. Benson, Carlos A. Garay, Michael S. Wertheim, Grace Shumaker, Jayne S. Gurtler, Jonathan Polikoff, Debra S. Brandt, Sunil Gupta
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(23)
Purpose The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC). This multicenter study evaluated FU/LV with or without oxaliplatin in patients with metastatic CRC after disea
Autor:
Florent Mazuir, Olivier Rixe, Sanjiv S. Agarwala, Chung-Tsen Hsueh, John Sarantopoulos, A. Craig Lockhart, Sharona Ross, Claudine Wack, Wendy Zhang, Jayne S. Gurtler, Jian Y. Yin
Publikováno v:
Journal of Clinical Oncology. 31:126-126
126 Background: Cabazitaxel (Cbz) is approved in combination with prednisone/prednisolone for the treatment of men with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. In vitro studies s